Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial - Corbacioglu, Selim; Lode, Holger; Ellinger, Susanne; Zeman, Florian; Suttorp, Meinolf; Escherich, Gabriele; Bernig, Toralf; Greil, Johann (The lancet. Oncology, 2024)
Online verfügbar: 24. Juni 2024